Small RNA Sequencing. Female Scientist in front of Hamilton Microlab® STAR

CeGaT Automates NGS Library Preparation for TMB and MSI Analysis

To ensure an even higher sample throughput, CeGaT has decided to automate the protocols for library preparation used for the analyses of Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI). The automation of the NGS libraries allows CeGaT to perform three times the number of samples per run, while almost halving the hands-on time, as CaseStudy shows.

CeGaT is a genetic diagnostics company that is very active in the field of oncology. The company is not only involved in various clinical research projects but also offers numerous services for Next-Generation-Sequencing (NGS). Two of the most popular analyses in precision medicine oncology are the analysis of tumor mutation burden (TMB) and the analysis of microsatellite instability (MSI). The analysis of these two biomarkers is the basis of immunotherapy, which has revolutionized oncology. Biomarkers are necessary to assess the effect of treatment and support the promising development of new immunotherapy combinations.

To increase sample throughput and reproducibility of results, CeGaT has decided to automate two workflows of the next-generation sequencing (NGS) library preparation protocols used for analysis through their in-house somatic tumor and for analysis through WES. The Hamilton Liquid handling platforms provide CeGaT with the flexibility needed to develop and automate NGS’s library preparation workflow.

The automation of the workflows for NGS library preparation significantly increases the efficiency and reproducibility of the assay by

  • allowing the processing of more samples per run,
  • reducing the hands-on time and
  • reducing the probability for errors, thanks to the full traceability of the samples

Find more information in the CaseStudy.

CeGaT is currently working on further automation of new NGS-based assays for oncology and automates further NGS-based analyses in different areas of biology and life science’. For the future, CeGaT wants to expand its portfolio and automate as many methods as possible. Our goal is to provide the highest quality standards for sample analysis while remaining adaptable to the rapidly evolving NGS methods. It is crucial for us to always use the most modern technology and keep developing ourselves to offer you the most innovative and best sequencing technology in the long run and thus be the best choice for you.

Innovation is essential for us. We are continuously expanding our product portfolio to apply the latest developments in genetic diagnostics.